logo
How related are dire wolves and gray wolves? The answer might surprise you.

How related are dire wolves and gray wolves? The answer might surprise you.

Yahoo24-05-2025

When you buy through links on our articles, Future and its syndication partners may earn a commission.
In a controversial announcement earlier this month, scientists with the company Colossal Biosciences claimed they have brought back dire wolves from extinction using genetic engineering.
Dire wolves (Aenocyon dirus) lived in North America during the last ice age and died out around 12,500 years ago, but fossils have preserved enough of these predators' DNA for researchers to partly reconstruct their genome.
The announcement drew criticism from paleogeneticists and other experts, who argued that the newly created animals — three snow-white pups named Romulus, Remus and Khaleesi — are only like dire wolves in appearance and so are not true dire wolves. To "resurrect" the dire wolf, Colossal scientists made 20 tweaks to 14 genes in a modern-day gray wolf (Canis lupus) genome, modifying characteristics like body size and hair color.
"Colossal has said that the gray wolf and dire wolf genomes are 99.5% identical, but that is still 12,235,000 individual differences," Nic Lawrence, a paleogeneticist and associate professor at the University of Otago in New Zealand, told Vox. 'So a gray wolf with 20 edits to 14 genes, even if these are key differences, is still very much a gray wolf.'
In addition to the tiny number of DNA changes, experts pointed out that dire wolves and gray wolves aren't closely related in evolutionary terms. While the two species share many physical traits and the wolf-pack social structure, a seminal study published in 2021 in the journal Nature indicated that dire wolves aren't technically wolves.
Related: Reintroducing wolves to Yellowstone helped entire ecosystem thrive, 20-year study finds
According to the study, dire wolves branched off from modern wolf-like canids — a group that includes gray wolves, coyotes (Canis latrans), dholes (Cuon alpinus), African wild dogs (Lycaon pictus) and African jackals — roughly 5.7 million years ago.
So just how closely related are dire wolves and grey wolves — and what does the best available evidence tell us about the evolutionary relationship between these species?
The latest peer-reviewed research suggests that dire wolves and gray wolves are only distantly related, Mairin Balisi, a paleontologist and curator at the Raymond M. Alf Museum of Paleontology in California, told Live Science in an email.
In the 2021 study, scientists found that dire wolves and gray wolves share a last common ancestor 5.7 million years ago during a period known as the late Miocene, said Balisi, who studies the evolution of mammalian carnivores but did not contribute to the 2021 study.
The analysis, which was based on DNA extracted from five dire wolf fossils, "showed that dire wolves diverged from the ancestor of not just gray wolves, of not just the group comprising [gray wolves and their closest relatives], but of all wolf-like canids including African jackals," Balisi said. "This distant relationship justifies the genus name Aenocyon for dire wolves differing from the genus name Canis for most other wolf-like canids."
The 2021 study revealed what was a decidedly blurry picture of canid evolution. "Previously scientists had interpreted dire and gray wolves to be sister species, or at least cousins through another extinct large wolf, Canis armbrusteri, because of strong similarity in their bones and teeth," Balisi said. C. armbrusteri lived in North America during the last ice age and was likely an ancestor of dire wolves, according to the study.
Previous research also placed the split between dire wolves and gray wolves much later than the 2021 study, with dates ranging between 2 million years ago and 2.5 million years ago, Balisi said.
The 2021 study clarified some aspects of canid evolution, but many questions remain unanswered. For example, it's still unclear which wolf-like canids are most closely related to dire wolves, Balisi said.
It's entirely possible that dire wolves are more closely related to African jackals than gray wolves, she said, despite their physical appearance being closer to gray wolves, adding that "future analyses on more and/or higher-quality genomic data may shed more light on the fine-scale relationships among these canids."
African jackals are divided into two species — the black-backed jackal (Canis mesomelas), native to eastern and southern Africa, and the side-striped jackal (Canis adustus), native to sub-Saharan and southern Africa. The 2021 study found that African jackals diverged from other wolf-like canids around 5.1 million years ago, forming their own branch on the evolutionary tree approximately 600,000 years after dire wolves formed theirs.
Fossils show that dire wolves were larger than modern-day gray wolves and had more robust jaws and teeth, which enabled them to take down larger prey. Current studies of canid evolution rely on these fossils to determine the relationships between species, but the record may have erased crucial information, Balisi said. "It is possible that other traits that don't fossilize as readily also set apart dire wolves from gray wolves today," she said.
There is also a question mark over whether dire wolves and gray wolves ever interbred. While it is possible that they did, the 2021 study found no evidence for gene flow between the two species, or between dire wolves and coyotes, Balisi said.
"Wolf-like canids do hybridize today — e.g., gray wolves and coyotes — so interbreeding between dire and gray wolves may have happened and just has yet to be detected," Balisi said. But gray wolves and coyotes are much more closely related to each other than gray wolves and dire wolves, so it may be that the latter two have evolved bigger reproductive differences, she said.
Following Colossal's announcement, the company uploaded a paper to the preprint database bioRxiv with new (but not yet peer-reviewed) findings about the dire wolf's evolutionary history.
RELATED STORIES
—Wolves in Ethiopia spotted licking 'red hot poker' flowers like lollipops
—Dogs may have domesticated themselves because they really liked snacks, model suggests
—Yellowstone's 'queen of the wolves' killed by rival pack after living to 11 years old and having 10 litters of pups
The results, based on two fossils dating to 13,000 and 72,000 years ago, suggest that dire wolves descended from a lineage that was itself born from interbreeding between two lineages: a sister lineage to the one that produced modern-day South American canids (Cerdocyonina) and a sister lineage to the one that produced the African wild dog.
The research may shed light on how dire wolves evolved as a species, but it does not claim to rewrite the findings of the 2021 study. Overall, the new clues "may be a valid update to the literature," so long as they hold up to peer review, Balisi said.
Regardless of whether peer review deems the study robust, the currently available evidence tells us that dire wolves and gray wolves are not closely related, which means that Romulus, Remus and Khaleesi are not dire wolves.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation
Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation

Washington Post

time2 hours ago

  • Washington Post

Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation

NEW YORK — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week . They include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a leading critic of pandemic-era lockdowns, and a professor of operations management.

Enough hype about AI in health—let's talk about results
Enough hype about AI in health—let's talk about results

Fast Company

time2 hours ago

  • Fast Company

Enough hype about AI in health—let's talk about results

There's no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative to fund AI infrastructure, while the UK government announced £82.6 million in research funding for three projects, two of which are using AI to tackle cancer and Alzheimer's disease. But ask any patient waiting for a diagnosis, or a clinician searching for certainty, and the real question cuts through all the noise: When will all the innovation deliver real impact where it matters most? We've entered an era where healthcare data is measured in exabytes—genomes, images, clinical notes, labs, and signals from every continent. At SOPHiA GENETICS, we've just achieved the milestone of analyzing 2 million patient profiles. It's a number that was unimaginable a decade ago. Yet the value of data isn't in volume. It's what you do with it. Insight matters only if it changes an outcome, shortens a diagnostic odyssey, or opens up a new chance for a patient. It's time to move from conversation to action. Too often, insights get trapped in institutional silos or left in endless pilot projects, just out of reach of the people who need them. 3 ways AI is already transforming medicine Today, technology can connect, for example, a patient in São Paulo with expertise in Seoul, uncovering patterns invisible to the human eye. Here are several ways AI is helping now. 1. Improving diagnostic accuracy: AI algorithms, particularly those based on deep learning, have demonstrated remarkable accuracy in diagnosing diseases from medical images and test results. These systems are trained on vast datasets, allowing them to recognize patterns and anomalies that might be missed by the human eye. For example, in dermatology, AI systems trained on images of skin lesions have shown the ability to detect skin cancers, such as melanoma, with high levels of precision. 2. Enhancing cancer prevention: AI techniques can be used to screen individuals for genomic markers and develop personalized cancer risk prediction scores. This proactive approach can help screen younger patients for genomic predispositions, empowering them to make informed prevention decisions and proactively monitor their health. 3. Tailoring treatments to genomic profiles: One of the most significant applications of AI is in the field of genomics. AI can analyze vast genomic datasets to identify mutations and variations that might influence an individual's response to certain treatments. For example, our SOPHiA DDM product can identify specific genomic markers that are susceptible to targeted cancer therapies, increasing the efficacy of the treatment and minimizing the risk of adverse reactions, for a more effective and safer treatment plan for patients. To scale up these AI applications there are many regulatory and compliance barriers to overcome. This requires investment in data security, creating clear guidelines, data security measures, and ensuring clinicians are fully trained. Our goal should be to create a regulatory environment that fosters innovation while safeguarding patient data and promoting public trust. We must democratize this powerful data to enable more physicians, practices, and hospitals to incorporate AI into daily clinical use so that a greater number of patients can access data-driven medicine, not just a select few. My message for governments investing in AI is clear: Balance investing in future AI tools with validating existing solutions that have already been proven to improve patient outcomes. Build the bridges that turn breakthroughs into benefits, so that data-driven medicine becomes a reality for every patient.

Fast Five Quiz: Diffuse Large B-Cell Lymphoma
Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Medscape

time2 hours ago

  • Medscape

Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Although diffuse large B-cell lymphoma (DLBCL) is characterized by aggressive clinical behavior, standard treatment can provide good long-term survival outcomes. However, management can be complex, with certain comorbidities exacerbating disease severity and complications such as extranodal involvement significantly affecting prognosis. Understanding the nuances of DLCBL presentation, diagnosis, and management is key to delivering the best outcomes to patients affected by this rapidly progressive disease. What do you know about DLBCL? Check your knowledge with this quick quiz. Both primary and secondary Sjögren syndrome are strongly associated DLBCL. Other autoimmune disorders that have been associated with DLBCL include hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. In addition to autoimmune disorders, viral infections have also been linked to DLBCL; these include HIV, hepatitis B, hepatitis C, and Epstein-Barr. Further, data have shown that patients with rheumatic diseases have a heightened risk of DLBCL development. Though fugal or bacterial pneumonia, humoral deficiency, and bone infections (such as osteomyelitis) can occur in patients with DLBCL, data have indicated that survivors of DLBCL were more likely to experience these conditions, rather than being strongly linked to DLBCL itself. Learn more about DLBCL staging. In the NCCN's guidelines, PET/CT is the preferred modality for imaging in DLBCL workup. C/A/P CT with contrast can also be used in a complementary setting to help stage the disease and identify other factors such as extranodal disease or visceral involvement, but it is not preferred. Although not essential, head CT/MRI or neck CT/MRI with contrast (as well as bone marrow biopsy) can be useful for workup in selected cases. Specifically, bone marrow biopsy can be helpful in identifying indolent or low-volume disease. However, the NCCN notes that bone marrow biopsy is not needed if PET/CT shows bone disease. Learn more about DLBCL workup. Data indicate that extranodal involvement occurs in approximately 30%– 50% of patients with DLBCL; further, it is reported that gastrointestinal involvement is the most common extranodal site. Other affected sites include the skin, bones, spleen, and central nervous system; kidneys, testicles, and the liver can also be impacted, but they are not regarded as the most common. Learn more about DLCBL and extranodal involvement. A population-based study involving over 30,000 patients with extranodal DLBCL found that the best outcomes are associated with heart and mediastinal sites, with a 42% reduction in mortality risk compared with involvement of the intestinal tract. Involvement of the pancreas and hepatobiliary system, respiratory system, or nervous system are associated with significantly greater risks of mortality compared with the intestinal tract. Other factors associated with greater mortality risk include late age at onset, history of other malignancy, late age at presentation, and Black, non-Hispanic ethnicity. Learn more about DLBCL prognosis. CAR T therapy is typically utilized as a second-line treatment for patients with relapsed/refractory DLBCL. CD19-directed CAR T-cell therapy is considered ' the standard of care' for relapsed/refractory DLBCL, with three treatments approved for this population. Although a number of factors can lead to CAR T cell therapy resistance, the key mechanism is typically down regulation or loss of CD19 expression. Abnormal differentiation and dysfunction of T cells can also cause poor response to CAR T therapy, and being unable to collect enough T cells can also negatively affect the impact of CAR T products; however, these factors are not considered key mechanisms for resistance to CAR T-cell therapy. As such, early collection of T-cells in high-risk patients with DLBCL is one strategy to ensure enough T cells are available when needed. Partial response or relapse after CAR T therapy should prompt third-line therapy, such as alternative systemic therapy not previously given, clinical trial, palliative involved-site radiation therapy, or best supportive care. Learn more about relapsed or refractory DLBCL.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store